Recital 19, Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 11×

The chief task of the Agency should be to provide Community institutions and Member States with the best possible scientific opinions so as to enable them to exercise the powers regarding the authorisation and supervision of medicinal products conferred on them by Community legislation in the field of medicinal products. Only after a single scientific evaluation procedure addressing the quality, safety and efficacy of high-technology medicinal products has been conducted by the Agency, applying the highest possible standards, should marketing authorisation be granted by the Community, and this should be done by means of a rapid procedure ensuring close cooperation between the Commission and Member States.

The 10 that are cited most themselves, of 11.

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Next, it must be noted that, according to recital 19 of Regulation No 726/2004, the chief task of the EMA should be to provide EU institutions and Member States with the best possible scientific opinions so as to enable them to exercise …

    5 May 2021 · 62018TJ0611

  • Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision

    It is apparent from the preamble to Regulation No 726/2004 (see in particular recital 19) that the centralised procedure for the authorisation of medicinal products provided for in that regulation is based on a scientific evaluation …

    19 Dec 2019 · 62018TJ0211

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Recitals 17 and 19 of Regulation No 726/2004 state: [The European Union] should have the means to carry out a scientific evaluation of the medicinal products presented in accordance with the decentralised … authorisation procedures. …

    16 Mar 2023 · 62021CJ0438

  • Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v European Commission.Decision

    Recitals 7, 8 and 19 of Regulation No 726/2004 state: Experience gained since the adoption of Council Directive 87/22/EEC of 22 December 1986 on the approximation of national measures relating to the placing on the market of …

    22 Jun 2023 · 62021CJ0006

  • Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision

    À cet égard, il convient de rappeler que, ainsi qu’il ressort de l’exposé des motifs du règlement n o 726/2004 (voir notamment considérant 19), la procédure centralisée d’autorisation des médicaments qu’il prévoit repose …

    2 Mar 2022 · 62020TJ0556

  • Opinion of Advocate General Medina delivered on 6 October 2022. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Recitals 9 and 19 of Regulation 726/2004 declare: As regards medicinal products for human use, optional access to the centralised procedure should also be provided for in cases where use of a single procedure produces added value for the …

    6 Oct 2022 · 62021CC0438

  • Judgment of the Court (Fourth Chamber) of 14 March 2024. Debregeas et associés Pharma (D & A Pharma) v European Commission and European MediDecision

    The Commission argues that the applicable legislation does not entitle MA applicants to require the CHMP to consult the scientific group of their choice. The absence of such a right is consistent with the purpose of that legislation, which …

    14 Mar 2024 · 62022CJ0291

  • Opinion of Advocate General Medina delivered on 7 September 2023. Debregeas et associés Pharma (D & A Pharma) v European Commission and EuroDecision

    As the General Court notes in paragraph 51 of the judgment under appeal, the choice of a standing SAG depends, first, based on a joint reading of Article 11(2) of the CHMP Rules of Procedure and point 6.1 of the Guidelines on the …

    7 Sep 2023 · 62022CC0291

  • Judgment of the General Court (Fourth Chamber) of 11 February 2026. Mylan Ireland Ltd v European Commission.Decision

    According to the applicant, the contested decision is based on outdated scientific evidence, whereas the legal framework for MAs requires scientific progress to be taken into consideration. The applicant observes in that regard that …

    11 Feb 2026 · 62023TJ1181

  • Judgment of the General Court (Fourth Chamber) of 11 February 2026. Neuraxpharm Pharmaceuticals SL v European Commission.Decision

    According to the applicant, the contested decision is based on outdated scientific evidence, whereas the legal framework for MAs requires scientific progress to be taken into consideration. The applicant observes in that regard that …

    11 Feb 2026 · 62023TJ1182